4//SEC Filing
Baldry Mark 4
Accession 0001628280-23-036756
CIK 0001501697other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 4:39 PM ET
Size
5.5 KB
Accession
0001628280-23-036756
Insider Transaction Report
Form 4
Baldry Mark
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-11-01$0.73/sh−10,257$7,488→ 24,690 total
Footnotes (3)
- [F1]These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
- [F2]Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001644137
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 4:39 PM ET
- Size
- 5.5 KB